Nasdaq:PSTV
PLUS THERAPEUTICS, INC.
A clinical-stage biopharmaceutical firm developing novel therapies for rare diseases and oncology with a focus on advancing its proprietary asset pipeline.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to the high-risk, high-reward potential of its novel therapies in lucrative rare disease markets with limited competition. If key assets advance through clinical trials and receive FDA approval, the company could transition from a cash-burning entity to a profitable biopharmaceutical business. The current marketable securities position of $3.5M provides some liquidity buffer against immediate operational pressures.
Bear Case
The company faces severe financial distress with total liabilities of $15.6M exceeding shareholders' equity of -$8.9M, creating a negative net asset position. Persistent negative cash flow from investing and financing activities indicates an inability to generate organic growth or self-sustain without constant capital raises. The lack of revenue growth over five years and high operating expenses relative to minimal current assets pose existential threats.
About PLUS THERAPEUTICS, INC.
PLUS Therapeutics (PSTV) is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases and oncology. The company primarily serves the specialized pharmaceutical market with a portfolio of assets targeting unmet medical needs, though recent financials indicate significant operational losses. Its business model relies heavily on research and development investments to advance its pipeline toward potential regulatory approval.
Analysis
Management Discussion
The company reported a net loss of $13.0M in 2024, continuing a trend of substantial losses from -$20.3M in 2022 to -$13.3M in 2023. Operating expenses of $20.5M significantly exceeded revenue of $5.8M, resulting in a negative operating profit of -$14.7M, while cash flow from operations was -$10.6M driven by heavy R&D spending and non-cash adjustments.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high regulatory barriers, and significant upfront investment required before generating commercial revenue. Companies in this space often operate at a loss for many years while advancing their drug pipelines through clinical trials toward market approval. Success depends heavily on securing substantial financing to fund R&D until products reach the marketplace.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $5.8M |
| Cost of Revenue | $-224.0K | $-4.9M | $0 |
| Gross Profit | $224.0K | $4.9M | $5.8M |
| Operating Expenses | $19.9M | $18.2M | $20.5M |
| Operating Income | $-19.7M | $-13.3M | $-14.7M |
| R&D | — | $9.7M | $10.6M |
| G&A | $10.2M | $8.5M | $9.9M |
| Stock-Based Comp | $606.0K | $569.0K | $550.0K |
| D&A | $619.0K | $628.0K | $723.0K |
| Depreciation | $500.0K | $600.0K | $600.0K |
| Amortization | $100.0K | $100.0K | $100.0K |
| Other OpEx | $9.7M | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $711.0K | $395.0K | — |
| Interest Income | $147.0K | $400.0K | $273.0K |
| Pre-Tax Income | $-19.7M | $-13.3M | $-14.7M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-19.7M | $-13.3M | $-14.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-20.3M | $-13.3M | $-13.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-20.3M | $-13.3M | $-13.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $21.8M | $9.8M | $5.3M |
| Cash & Equivalents | $18.1M | $8.6M | $76.0K |
| Marketable Securities | — | — | $3.5M |
| Other Current Assets | $3.7M | $1.3M | $1.7M |
| Long-Term Assets | $2.0M | $1.6M | $1.4M |
| PP&E (Net) | $1.3M | $906.0K | $448.0K |
| Goodwill | $372.0K | $372.0K | $372.0K |
| Operating Leases | $248.0K | $202.0K | $73.0K |
| Other LT Assets | $106.0K | $74.0K | $481.0K |
| Total Assets | $23.9M | $11.4M | $6.6M |
| Current Liabilities | $11.9M | $10.7M | $15.6M |
| Accounts Payable | $8.4M | $4.8M | $9.5M |
| Current Debt | $1.6M | $4.0M | — |
| Current Leases | $110.0K | $120.0K | $44.0K |
| Other Current Liab | $1.8M | $1.9M | $6.0M |
| Long-Term Liabilities | $5.6M | $2.0M | $31.0K |
| Long-Term Debt | $3.8M | — | — |
| LT Operating Leases | $141.0K | $85.0K | $31.0K |
| Other LT Liab | $1.6M | $1.9M | $-3.3M |
| Total Liabilities | $17.4M | $12.7M | $15.6M |
| Shareholders' Equity | $6.4M | $-1.3M | $-8.9M |
| Paid-In Capital | $473.6M | $479.3M | $485.0M |
| Retained Earnings | $-467.2M | $-480.5M | $-493.5M |
| Total L&E | $23.9M | $11.4M | $6.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-20.3M | $-13.3M | $-13.0M |
| Non-Cash Adjustments | $-3.0M | $6.7M | $-1.9M |
| Working Capital Changes | $10.3M | $-6.2M | $4.4M |
| Cash from Operations | $-13.0M | $-12.9M | $-10.6M |
| Capital Expenditures | — | — | $146.0K |
| Cash from Investing | $-759.0K | $-160.0K | $-4.1M |
| Debt Repayments | $1.6M | $1.6M | $4.0M |
| Cash from Financing | $13.5M | $3.4M | $6.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-280.0K | $-9.6M | $-8.5M |
| Beginning Cash | $18.4M | $18.1M | $8.6M |
| Ending Cash | $18.1M | $8.6M | $76.0K |
Frequently Asked Questions
How does PLUS THERAPEUTICS, INC. make money?
The company's revenue is derived from its core pharmaceutical development efforts, specifically in the realms of rare disease treatments and oncology. Financial data suggests operations are currently funded through financing activities rather than commercial sales, indicating a pre-revenue or early-stage commercialization phase for its primary therapeutic candidates.
What are the main risks for PSTV?
Significant accumulated deficit with a retained earnings deficit of -$493.5M indicating reliance on external capital to sustain operations. Consistent net losses over the last three years totaling over $46M in cash burn without demonstrated revenue growth. High accounts payable relative to current assets suggests potential liquidity constraints or working capital management challenges.
What is PSTV's competitive advantage?
Access to proprietary intellectual property and novel drug mechanisms that address significant unmet medical needs in rare disease populations. Strong potential for high-margin revenue streams upon successful regulatory approval and commercial launch of its therapeutics. Strategic partnerships or licensing deals could provide non-dilutive funding and market access, though current debt levels suggest caution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.